Predictors of lung injury during durvalumab maintenance therapy following concurrent chemoradiotherapy in unresectable locally advanced non‐small cell lung carcinoma

BACKGROUND: Based on the results of the PACIFIC trial, maintenance with durvalumab has emerged as the standard treatment following concurrent chemoradiotherapy in patients with unresectable locally advanced non‐small cell lung carcinoma (NSCLC). However, adverse events attributed to durvalumab, espe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirama, Nobuyuki, Yamamoto, Masaki, Nagaoka, Satoshi, Segawa, Wataru, Sugimoto, Chihiro, Nagayama, Hirokazu, Hiro, Shuntaro, Kajita, Yukihito, Maeda, Chihiro, Kubo, Sousuke, Seki, Kenichi, Nagahara, Yoshinori, Teranishi, Shuhei, Tashiro, Ken, Hara, Yu, Kobayashi, Nobuaki, Watanabe, Shigenobu, Kudo, Makoto, Kaneko, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481134/
https://www.ncbi.nlm.nih.gov/pubmed/37533115
http://dx.doi.org/10.1111/1759-7714.15042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481134/
https://www.ncbi.nlm.nih.gov/pubmed/37533115
http://dx.doi.org/10.1111/1759-7714.15042

Ejemplares similares